TACT Reviews
A non-confidential summary of the TACT report is detailed below however interested parties and potential funders are encouraged to contact the researcher directly to request a copy of the full TACT report.
October
|
HT-100 - Halofuginone |
DMD |
|
| Marc B Blaustein MPP Halo Therapeutics LLC |
A randomised, double-blind, placebo-controlled, multiple-dose, dose-escalation study to evaluate the safety, tolerability, pharmacokinetic, and pharmacodynamic effects of HT-100 in patients with Duchenne muscular dystrophy | ||
Naproxcinod - HCT 3012 |
BMD |
||
| Fabrizio Dolfi NicOx SA |
A 6-month multicenter, randomised, double-blind, placebo-controlled, Phase IIa proof of principle study of naproxcinod (HCT 3012) 750 mg bid in patients with Becker Muscular Dystrophy. | ||
Human Embryonic Stem Cell Derived Motor Neuron Progenitors |
SMA |
||
| Chris N Airriess California Stem Cell |
Human Embryonic Stem Cell Derived Motor Neuron Progenitors for the Treatment of Motor Neuron Disease. | ||
January
|
Tetracycline Derivatives |
SMA |
|
| Dr Higgins Paratek Pharmaceuticals |
Tetracycline Derivatives as SMN2 Splicing Modifiers for the Treatment of SMA. Screen of a tetracycline library -identified a group of potential candidates. One of these will be selected as a final candidate. | ||
GsMTx4 |
DMD |
||
| Dr Sachs Rose Pharmaceuticals |
Therapy for Muscular Dystrophy by Inhibition of Mechanosensitive Ion Channels. | ||
June
|
N-Acetyl cysteine |
CMD |
|
| Dr Ferreiro Institute of Myology |
Oxigem: AntiOXIdants for a GEnetic Myopathy. The First Clinical Trial for a Congenital Muscle Disorder: N-Acetyl cysteine (NAC) Treatment for SEPN1 Related Myopathy. | ||
P-188 |
DMD |
||
| Dr Symons Phrixus Pharmaceuticals |
An open-label, fixed dose, exploratory study to assess the efficacy and safety of P-188 NF on left ventricular volume changes in patients with Duchenne muscular dystrophy (DMD) | ||
Laminin-111 |
DMD |
||
| Dr Hodges Prothelia Inc |
Recombinant human Laminin-111 for treatment of Duchenne Muscular Dystrophy | ||
February
|
lisinopril / Losartan |
DMD |
|
| Dr Chris Spurney Children's National Medical Center |
Treatment of early cardiac systolic dysfunction in Duchenne muscular dystrophy with lisinopril or Losartan: a prospective, randomized, blinded, crossover trial. | ||
Isosorbide dinitrate plus Ibuprofen |
DMD |
||
| Professor Clementi & Dr D'Angelo L Sacco University Hospital |
A pharmacological treatment for muscular dystrophy combining NO-releasing and non steroidal anti-inflammatory drugs. | ||
Flavocoxid |
DMD |
||
| Professor Vita & Dr Messina University of Messina |
Randomized double-blind placebo-controlled trial of flavocoxid in Duchenne muscular dystrophy. | ||
05 Jan 2012
